Katherine C Kurnit1, Rebecca A Previs2, Pamela T Soliman1, Shannon N Westin1, Ann H Klopp3, Bryan M Fellman4, Karen H Lu1, Lois M Ramondetta1, Nicole D Fleming5. 1. Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. 2. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, United States of America. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. 5. Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States of America. Electronic address: nfleming@mdanderson.org.
Abstract
OBJECTIVE: Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcoma patients. METHODS: We performed a retrospective cohort study of women with stage I or II uterine carcinosarcoma at our institution between March 1990 and June 2016. All pathology had been reviewed and confirmed by gynecologic pathologists. Data were extracted from the electronic medical record. Descriptive and comparative statistics were used to compare clinicopathologic characteristics. Univariable and multivariable analyses were performed for survival outcomes. RESULTS: 140 patients were identified. Median age was 67 years (range: 36-91). Median follow-up was 39.1 months (2.9-297.4). The majority of patients had stage IA (67%) versus stage IB (21%) or stage II (11%) disease. The majority of patients (63%) received adjuvant treatment: vaginal brachytherapy only (14%); whole pelvic radiation therapy only (16%); chemotherapy only (n = 13, 9%); combination chemotherapy and vaginal brachytherapy (15%); combination chemotherapy and whole pelvic radiation (9%). 52 patients (37%) received no adjuvant therapy. Median overall survival (OS) was 48.0 months (95% CI 32.7-80.9). On multivariable analysis for OS, advancing age (HR 1.05, 95% CI 1.03-1.08, p < 0.001), higher stage (stage IB: HR 1.64, 95% CI 0.91-2.95, p = 0.10; stage II: HR 3.04, 95% CI 1.51-6.13, p = 0.002), and the presence of a rhabdomyosarcoma component (HR 1.66, 95% CI 1.02-2.70, p = 0.04) were significantly associated with worse OS. CONCLUSIONS: Advancing age, stage, and the presence of a rhabdomyosarcoma component were all associated with worse OS in patients with early stage uterine carcinosarcoma. New treatment algorithms should incorporate factors aside from stage alone.
OBJECTIVE: Evaluate the impact of clinicopathologic characteristics and adjuvant treatment on survival outcomes in early stage uterine carcinosarcomapatients. METHODS: We performed a retrospective cohort study of women with stage I or II uterine carcinosarcoma at our institution between March 1990 and June 2016. All pathology had been reviewed and confirmed by gynecologic pathologists. Data were extracted from the electronic medical record. Descriptive and comparative statistics were used to compare clinicopathologic characteristics. Univariable and multivariable analyses were performed for survival outcomes. RESULTS: 140 patients were identified. Median age was 67 years (range: 36-91). Median follow-up was 39.1 months (2.9-297.4). The majority of patients had stage IA (67%) versus stage IB (21%) or stage II (11%) disease. The majority of patients (63%) received adjuvant treatment: vaginal brachytherapy only (14%); whole pelvic radiation therapy only (16%); chemotherapy only (n = 13, 9%); combination chemotherapy and vaginal brachytherapy (15%); combination chemotherapy and whole pelvic radiation (9%). 52 patients (37%) received no adjuvant therapy. Median overall survival (OS) was 48.0 months (95% CI 32.7-80.9). On multivariable analysis for OS, advancing age (HR 1.05, 95% CI 1.03-1.08, p < 0.001), higher stage (stage IB: HR 1.64, 95% CI 0.91-2.95, p = 0.10; stage II: HR 3.04, 95% CI 1.51-6.13, p = 0.002), and the presence of a rhabdomyosarcoma component (HR 1.66, 95% CI 1.02-2.70, p = 0.04) were significantly associated with worse OS. CONCLUSIONS: Advancing age, stage, and the presence of a rhabdomyosarcoma component were all associated with worse OS in patients with early stage uterine carcinosarcoma. New treatment algorithms should incorporate factors aside from stage alone.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Gregory Sutton; James Kauderer; Linda F Carson; Samuel S Lentz; Charles W Whitney; Holly Gallion Journal: Gynecol Oncol Date: 2005-03 Impact factor: 5.482
Authors: Mona Hosh; Sarah Antar; Ahmed Nazzal; Mahmoud Warda; Ahmed Gibreel; Basel Refky Journal: Int J Gynecol Cancer Date: 2016-07 Impact factor: 3.437
Authors: Howard D Homesley; Virginia Filiaci; Maurie Markman; Pincas Bitterman; Lynne Eaton; Larry C Kilgore; Bradley J Monk; Frederick R Ueland Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Nisha Bansal; Thomas J Herzog; Venkatraman E Seshan; Peter B Schiff; William M Burke; Carmel J Cohen; Jason D Wright Journal: Obstet Gynecol Date: 2008-07 Impact factor: 7.661
Authors: Elizabeth L Dickson; Rachel Isaksson Vogel; Paola A Gehrig; Stuart Pierce; Laura Havrilesky; Angeles Alvarez Secord; Joseph Dottino; Amanda N Fader; Stephanie Ricci; Melissa A Geller Journal: Gynecol Oncol Date: 2015-09-06 Impact factor: 5.482
Authors: Jesus Gonzalez Bosquet; Shelby A Terstriep; William A Cliby; Monica Brown-Jones; Judith S Kaur; Karl C Podratz; Gary L Keeney Journal: Gynecol Oncol Date: 2009-11-05 Impact factor: 5.304
Authors: Matthew A Powell; Virginia L Filiaci; Martee L Hensley; Helen Q Huang; Kathleen N Moore; Krishnansu S Tewari; Larry J Copeland; Angeles A Secord; David G Mutch; Alessandro Santin; David P Warshal; Nick M Spirtos; Paul A DiSilvestro; Olga B Ioffe; David S Miller Journal: J Clin Oncol Date: 2022-01-10 Impact factor: 50.717
Authors: Sheila E Segura; Silvana Pedra Nobre; Yaser R Hussein; Nadeem R Abu-Rustum; Britta Weigelt; Robert A Soslow; Deborah F DeLair Journal: Am J Surg Pathol Date: 2020-11 Impact factor: 6.394
Authors: Kerri Beckmann; Sudarshan Selva-Nayagam; Ian Olver; Caroline Miller; Elizabeth S Buckley; Kate Powell; Dianne Buranyi-Trevarton; Raghu Gowda; David Roder; Martin K Oehler Journal: Cancer Manag Res Date: 2021-06-10 Impact factor: 3.989
Authors: Lori Cory; Colleen Brensinger; Robert A Burger; Robert L Giuntoli; Mark A Morgan; Nawar Latif; Lilie L Lin; Emily M Ko Journal: Gynecol Oncol Rep Date: 2022-01-17